Cerdelga FDA Approval History
FDA Approved: Yes (First approved August 19, 2014)
Brand name: Cerdelga
Generic name: eliglustat
Dosage form: Capsules
Company: Genzyme Corporation
Treatment for: Gaucher Disease
Cerdelga (eliglustat) is a glucosylceramide synthase inhibitor indicated for the long- term treatment of adult patients with Gaucher disease type 1.
Development timeline for Cerdelga
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
